Novo Nordisk NVO · NYSE
$38.55 -0.73% (-$0.29)
Summary
81 / 100 · Bulios Score
What speaks for it
- Out of every 100 DKK of revenue, 35 DKK is left as net profit.
- Revenue grew by 20% a year over the last 3 years.
- It earns 30 DKK a year on every 100 DKK of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
None of the indicators we track raises a caution right now.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 9.9 DKK for 1 DKK of yearly profit. Over the last five years it was 30.6 DKK on average.
Valuation in detailIs it growing?
Yes, fastRevenue (DKK)
Diluted EPS (DKK)
- Analyst estimate
Revenue grew by 19% a year over 5 years. Over the last 3 years it grew by 20% a year. For the next fiscal year analysts expect revenue to fall by 1.3%.
Growth in detailDoes it make money?
Very wellWhere 100 DKK of revenue goes
- Cost of sales 19 DKK
- Research and development 18 DKK
- Sales and administration 20 DKK
- Taxes and other 7.8 DKK
- Net profit 35 DKK
Net profit, industry median (Drug Manufacturers - General) 14 DKK
Out of every 100 DKK of revenue, 35 DKK is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
High, at risk- Yield
- 4.63%
- Paid out of profit
- 46%
- Raised in a row
- 1 year
You receive $1.80 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 23
- Hold 13
- Sell 3
Today's price within the analysts' price targets
The average target of $44.67 is 16% above today's price. 59% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
The company reports no revenue by product.
By region
- North America 63%
- EMEA 24%
- Rest of World 13%
North America brings in 63% of revenue.
Segments in detail